Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Naive or experienced patients with genotype 1 compensated cirrhosis~Exclusion Criteria:~* HIV and hepatitis B infection, active hepatocellular carcinoma (HCC), decompensated cirrhosis, history of organ transplant, severe psychiatric disorders or treatment with drugs that showed an interaction with antiviral treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- Group I (<65 years) (Type: ACTIVE_COMPARATOR): Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
- Group II (>65 years) (Type: ACTIVE_COMPARATOR): Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).